A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of SM-88 Used With Methoxsalen, Phenytoin, and Sirolimus (MPS) as Response Maintenance Therapy Following Standard Treatments for Patients With Ewing's Sarcoma or as Salvage Therapy for Patients With Clinically Advanced Sarcomas
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Methoxsalen (Primary) ; Phenytoin (Primary) ; Racemetyrosine (Primary) ; Sirolimus (Primary)
- Indications Ewing's sarcoma; Sarcoma
- Focus Therapeutic Use
- Acronyms HopES
- 07 Nov 2019 Planned End Date changed from 31 May 2022 to 31 Oct 2022.
- 07 Nov 2019 Planned primary completion date changed from 31 May 2020 to 31 Oct 2020.
- 07 Nov 2019 Status changed from not yet recruiting to recruiting.